Location History:
- Auburndale, MA (US) (2013 - 2015)
- Lexington, MA (US) (2017)
Company Filing History:
Years Active: 2013-2017
Title: Kyungmin Hahm: Innovator in Neurological Treatments
Introduction
Kyungmin Hahm is a notable inventor based in Auburndale, MA (US). He has made significant contributions to the field of neuroscience, particularly in the treatment of neurological disorders. With a total of 3 patents to his name, Hahm's work focuses on innovative methods for addressing complex medical conditions.
Latest Patents
Hahm's latest patents include groundbreaking methods for treating neurological disorders. One of his key inventions involves the use of TWEAK or TWEAK receptor blocking agents to treat neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders. Additionally, he has developed methods for treating TWEAK-related conditions, which encompass a wide range of health issues affecting the cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone, and cartilage systems. His inventions also provide methods for identifying TWEAK agonists or antagonists, as well as transgenic animals that express exogenous DNA encoding TWEAK polypeptides. Furthermore, Hahm's work includes methods for diagnosing diseases based on TWEAK expression and affecting cellular differentiation of progenitor cells using TWEAK polypeptides.
Career Highlights
Throughout his career, Kyungmin Hahm has worked with prominent companies in the biotechnology sector, including Biogen Idec MA Inc. and Biogen MA Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in medical research.
Collaborations
Hahm has collaborated with notable colleagues, including Linda C. Burkly and Timothy Zheng. These partnerships have further enhanced his research and development efforts in the realm of neurological treatments.
Conclusion
Kyungmin Hahm's innovative work in the treatment of neurological disorders showcases his dedication to advancing medical science. His patents reflect a commitment to improving patient outcomes through targeted therapies.